Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP238046.RARA7tcqQNQwcX387JYEqphCVJ2YtYCg5h2zdQR_1pKHg130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP238046.RARA7tcqQNQwcX387JYEqphCVJ2YtYCg5h2zdQR_1pKHg130_provenance.
• NP650991.RAcpm_n0QrJ0shHEfoS-Oi2MwtGt6NsHaBXXhcPVFBvCA130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650991.RAcpm_n0QrJ0shHEfoS-Oi2MwtGt6NsHaBXXhcPVFBvCA130_provenance.
• NP618425.RAjvqvmBFkjnKKu7u9DngjvFu_g_sSBb4X0cCvUNJb31E130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618425.RAjvqvmBFkjnKKu7u9DngjvFu_g_sSBb4X0cCvUNJb31E130_provenance.
• NP523415.RAXBPSM5zDVuk4GvXYJtMXcklyfcrQp8JtVCfvy6wrSBo130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP523415.RAXBPSM5zDVuk4GvXYJtMXcklyfcrQp8JtVCfvy6wrSBo130_provenance.
• NP860976.RAWDkN0g_Acvi04hyrVYXXimuEdSU5T4Hm181O0H2-bPA130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP860976.RAWDkN0g_Acvi04hyrVYXXimuEdSU5T4Hm181O0H2-bPA130_provenance.
• assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP572985.RAS8UsvwLwgjIXXXTxbUsDNAupJQ948P4dpNa1Krpekgo130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP572985.RAS8UsvwLwgjIXXXTxbUsDNAupJQ948P4dpNa1Krpekgo130_provenance.
• NP322861.RAVqwZQzOf01YC84i6ieD3A1jEz_fGYqWWHP_VvWTZHTQ130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP322861.RAVqwZQzOf01YC84i6ieD3A1jEz_fGYqWWHP_VvWTZHTQ130_provenance.
• NP708672.RAz4qddnoim63-5_uaYHdFQQEUvJ7IFxQ8m2E_6I2jRf8130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP708672.RAz4qddnoim63-5_uaYHdFQQEUvJ7IFxQ8m2E_6I2jRf8130_provenance.
• NP852987.RA30h3j_eLTiSrEYxpf_Zij_uemuEl7aaob9--jCtvRN4130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP852987.RA30h3j_eLTiSrEYxpf_Zij_uemuEl7aaob9--jCtvRN4130_provenance.
• assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP827897.RAWUkmjbGX5bV_DrGNEGysBIj4Xs9w06gZyVPvG1n0lqQ130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827897.RAWUkmjbGX5bV_DrGNEGysBIj4Xs9w06gZyVPvG1n0lqQ130_provenance.
• NP827905.RAeTHyVAdmXZgJtaIwGTuQ6A1TDf2xoF366YFTbyj0rAY130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827905.RAeTHyVAdmXZgJtaIwGTuQ6A1TDf2xoF366YFTbyj0rAY130_provenance.
• NP827899.RAmLjC_DGUqnBYcDkkj7dJHMYQSrtLX3x2zdqQNL4HNsU130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827899.RAmLjC_DGUqnBYcDkkj7dJHMYQSrtLX3x2zdqQNL4HNsU130_provenance.
• NP563757.RAwKMv2N5WwF8BrPexTn3YRgOkuMXJF4IP98kAeTDj5NU130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP563757.RAwKMv2N5WwF8BrPexTn3YRgOkuMXJF4IP98kAeTDj5NU130_provenance.
• NP538417.RA7i5u6KXTqxAQVe5pO9d1ZP7TSRasXEmCikSMevBWNkw130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP538417.RA7i5u6KXTqxAQVe5pO9d1ZP7TSRasXEmCikSMevBWNkw130_provenance.
• NP572678.RANe0VaeH4Dq0g_LySoMq0koBweHgyWDN6fE_RNl38Ywc130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP572678.RANe0VaeH4Dq0g_LySoMq0koBweHgyWDN6fE_RNl38Ywc130_provenance.
• NP324367.RAx01_eMPfXI7gXE7d_QZU5ghodpXH88Wi-6rVAeYnGtE130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP324367.RAx01_eMPfXI7gXE7d_QZU5ghodpXH88Wi-6rVAeYnGtE130_provenance.
• NP827904.RAKinDRXfDMAWYnQB0mVrGofB5DVvvHL8xRagbllrSXAA130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827904.RAKinDRXfDMAWYnQB0mVrGofB5DVvvHL8xRagbllrSXAA130_provenance.
• NP656443.RAzfED9qa8dF4CkOlT8Kh9wvS7-lA06ZRi7rfl8WjLW7s130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP656443.RAzfED9qa8dF4CkOlT8Kh9wvS7-lA06ZRi7rfl8WjLW7s130_provenance.
• NP821988.RA7Cidji6dUAFrkf3wGZdy2RJ1u7gs3CpiETUW0fjH55o130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP821988.RA7Cidji6dUAFrkf3wGZdy2RJ1u7gs3CpiETUW0fjH55o130_provenance.
• NP827893.RA2nsK4sLFpF5wWoA_-wHsEw8N3-2cWqHnlDTrSpIXLHg130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827893.RA2nsK4sLFpF5wWoA_-wHsEw8N3-2cWqHnlDTrSpIXLHg130_provenance.
• NP827894.RA2gmAE2thMAbCixFssySMlbpNgv-CIQhRVFkFfJjB1wc130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827894.RA2gmAE2thMAbCixFssySMlbpNgv-CIQhRVFkFfJjB1wc130_provenance.
• NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_provenance.
• NP827900.RA3QM5G5SsL2X4uelyuhdvFMeN2DN7C-XEp_qehOnbfMc130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827900.RA3QM5G5SsL2X4uelyuhdvFMeN2DN7C-XEp_qehOnbfMc130_provenance.
• NP827902.RAzq_LlNY7sXL8F8_24rKBsEQFQ_wSE_CaxkrAMe1YJEM130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827902.RAzq_LlNY7sXL8F8_24rKBsEQFQ_wSE_CaxkrAMe1YJEM130_provenance.